NCT01193699已完成1 期
An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained prior to any study specific screening activities and able to comply with this protocol.
- •Patients age ≥18 years
- •Confirmed diagnosis of PV according to either the WHO criteria (2008, appendix 6) or the PSVG (appendix 7) criteria plus JAK-2 positivity, including newly diagnosed, pre-treated and on cytoreductive therapy.
- •Eastern Cooperative Oncology Group performance status ≤ 2
- •If female of childbearing potential - have a negative urine pregnancy test result within 7 days prior to the scheduled first application of investigational product and agree to employ adequate birth control measures for the duration of the study.
- •Exclusion criteria:
- •Diagnosis of any other myeloproliferative disorder
- •Any clinically significant illness or surgery within 4 weeks prior to dosing
- •Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening
- •Uncontrolled hypertension (systolic > 150 mmHg and diastolic > 100 mmHg, or clinically significant (i.e. active) cardiovascular disease: CVA/stroke (≤ 3 months prior to enrolment), myocardial infarction (≤ 3 months prior to enrolment), significant coronary artery stenosis, unstable angina, New York Heart Association (NYHA) Class 2 or greater Congestive heart failure, or serious cardiac arrhythmia requiring medication.
- •Previous treatment with Interferon for PV
- •Concurrent treatment with cytoreductive agents other than Hydroxyurea and investigational agents of any type
- •History of malignant disease, including solid tumours and haematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years
- •History of severe allergic (like anaphylaxis) or hypersensitivity reactions (like angioedema), any known or suspected intolerance to the investigational product.
- •Use of any investigational drug or participation in any investigational drug study within the last 4 weeks
- •Clinically significant history or known presence of psychiatric disorders, including but not limited to depression, anxiety and sleep disorders
- •Organ transplant, past or planned
- •Inadequate liver function defined by serum (total) bilirubin > 2,5 x ULN and/ or AST and ALT > 2,5 x ULN
- •Clinically significant ECG findings
- •History of renal disease requiring haemodialysis or seizure disorder requiring anticonvulsant therapy
- •Pregnant or lactating females (pregnancy test to be assessed within 7 days prior to study treatment start)
- •Acute or chronic infections or autoimmune diseases (collagen diseases, polyarthritis, immune thrombocythemia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune disorder).
排除标准
- 未提供
研究组 & 干预措施
P1101
Experimental
干预措施: PEG-P-INF alpha-2b (P1101) (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD)
时间窗: The incidence of dose limiting toxicities (DLTs), which define the MTD are assessed continously until achievement of MTD.
The definition of MTD is based on a 3+3 dose escalation design. MTD is defined as the next lower dose of that dose which was considered to be untolerated (observed DLT frequency at least 2 out of 3 in one cohort or at least 2 out of six patients in 2 cohorts).
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study of Minnelide™ in Patients With Advanced GI TumorsAdvanced Gastrointestinal TumorsNCT01927965Minneamrita Therapeutics LLC45
已完成
1 期
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT00794781Eisai Inc.55
已完成
1 期
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaRelapsed/Refractory Diffuse Large B-Cell LymphomaNCT04436107BeiGene66
已完成
1 期
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsSolid TumorsNCT01862328Millennium Pharmaceuticals, Inc.64
终止
1 期
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)Acute Myelogenous LeukemiaNCT00486265AstraZeneca47